Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14. November 2024 13:10 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada
04. November 2024 12:00 ET
|
bioLytical Laboratories Inc.
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
04. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
Quality Smart Solutions Launches GRAS Experts to Protect Against Food Safety Risks
25. Oktober 2024 12:24 ET
|
Quality Smart Solutions Inc.
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- In light of McDonald’s recent recall of Quarter Pounders due to E. coli contamination, the need for stringent oversight on food ingredients has never been...
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
18. Oktober 2024 08:20 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
10. Oktober 2024 08:30 ET
|
Palisade Bio, Inc.
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
01. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
30. September 2024 19:07 ET
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
09. August 2024 18:28 ET
|
Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of